Target Audience — Nurse practitioners, nurses and oncology social workers at the intermediate and advanced levels involved in the care of patients with acute lymphoblastic leukemia (ALL).
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the various types and subtypes of acute lymphoblastic leukemia (ALL)|
|•||Identify tests used to diagnose disease and monitor treatment of ALL|
|•||Explain the overarching goals of treatment for the types of ALL|
|•||Explain approved and emerging treatment options for ALL, including stem cell transplantation, and the role of clinical trials|
|•||Describe the various roles the pharmacist plays in contributing to the management of patients with ALL|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for ALL|
Provided by The Leukemia & Lymphoma Society.
This activity is supported by an educational grant from The Leukemia & Lymphoma Society.
Continuing Education for Nurses, Social Workers and Nurse Practitioners
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award XX continuing education contact hours through the California Board of Registered Nursing.
Social Work Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive XX CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive XX CE clinical contact hours for this activity
Nurse Practitioners Credit Designation
This activity is approved for XX contact hour(s) of continuing education (which includes XX hour(s) pharmacology) by the American Association of Nurse Practitioners. Activity ID# xxxxxxxx. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Disclosure of Conflicts of Interest
All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Peter Campbell, PharmD, BCOP , is on the Advisory Board for Insys Therapeutics, Inc.
Ellen K, Richie, MD, has nothing to disclose.
Lauren Zikind, APN, NP-C, OCN, has nothing to disclose.
Disclaimer: The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Instructions for Credit: There is no fee for this activity. To receive credit for this CE activity, participants must review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to XX continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
|Estimated time to complete activity: XX hours|
|Date of initial release:|
|Valid for CME credit through|
Ellen Ritchie MD
Associate Professor of Clinical Medicine
Assistant Director of the Leukemia Program
Weill Cornell Medical College
New York, NY
Dr. Ritchie received her MD from Columbia College of Physicians and Surgeons and trained at New York Presbyterian Hospital at the Columbia College campus. For the last fifteen years, she has been a physician in the Leukemia Program at Weill Cornell Medical College. She is actively engaged in clinical research to find novel agents to treat leukemia, myelodysplastic syndrome and myeloproliferative disorders. She has a strong interest in the treatment of elderly patients and researches clinical interventions that can improve quality of life and outcome in these patients.
|Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager, Hematology/Oncology
Columbia University Irving Medical Center
New York, NY
Dr. Peter Campbell is an Oncology Clinical Pharmacist at NewYork-Presbyterian Hospital, Columbia University Irving Medical Center in New York, New York. Dr. Campbell’s area of specialized clinical practice is in acute and chronic leukemias, with a primary practice site of the inpatient setting. Dr. Campbell is also the Program Director for the PGY2 Oncology Pharmacy Residency at NewYork-Presbyterian Hospital.
Dr. Campbell graduated from St. John’s University College of Pharmacy and Allied Health Professions. He then completed a pharmacy practice residency followed by an oncology pharmacy specialty residency at NewYork-Presbyterian Hospital, and is also a Board Certified Oncology Pharmacist.
|Lauren Ziskind, APN, NP-C, OCN
Adult Leukemia Program
The University of Chicago
CLICK HERE to download the transcript for this activity.